Evidence map›Paper›PMID 39177498›Full record

ArticleNeuro-oncology2025

Mapping tumor habitats in isocitrate dehydrogenase -wild type glioblastoma: Integrating MRI, pathologic, and RNA data from the Ivy Glioblastoma Atlas Project.

Ji Eun Park, Joo Young Oh, Do Hoon Park, Ho-Su Lee, Shinkyo Yoon, NakYoung Kim, Seo Young Park, Sang Woo Song, Young-Hoon Kim, Chang-Ki Hong and 2 more

Abstract read
In one paragraph

Article in Neuro-oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Uncover This Tech Term: Tumor Habitat Analysis.Korean journal of radiology · 2026
    Article
  5. Modern Mining: The Role of Single-cell RNA Sequencing in Advancing Neuroscience Research.BioEssays : news and reviews in molecular, cellular and developmental biology · 2026
    Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Ji Eun ParkDepartment of Radiology and Research Institute of Radiology, University of Ulsan College of Medicine, Asan Medical Center, Seoul, South Korea.ORCID 0000-0002-4419-4682
Joo Young OhDepartment of Radiation Oncology, Yonsei Cancer Center, Seoul, South Korea.ORCID 0000-0003-2928-5073
Do Hoon ParkDepartment of Biochemistry and Molecular Biology, Asan Medical Center, Brain Korea 21 Project, University of Ulsan College of Medicine, Seoul, South Korea.ORCID 0000-0002-2983-0468
Ho-Su LeeDepartment of Biochemistry and Molecular Biology, Asan Medical Center, Brain Korea 21 Project, University of Ulsan College of Medicine, Seoul, South Korea.ORCID 0000-0003-3711-2180
Shinkyo YoonDepartment of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea.ORCID 0000-0001-7544-0404
NakYoung KimDynapex, LLC, Seoul, Korea.ORCID 0000-0001-8756-8587
Seo Young ParkDepartment of Statistics and Data Science, Korea National Open University, Seoul, Korea.ORCID 0000-0002-2702-1536
Sang Woo SongDepartment of Neurosurgery, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea.ORCID 0000-0002-5523-3798
Young-Hoon KimDepartment of Neurosurgery, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea.ORCID 0000-0002-8852-6503
Chang-Ki HongDepartment of Neurosurgery, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea.ORCID 0000-0002-2761-0373
Jeong Hoon KimDepartment of Neurosurgery, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea.ORCID 0000-0001-7131-4523
Ho Sung KimDepartment of Radiology and Research Institute of Radiology, University of Ulsan College of Medicine, Asan Medical Center, Seoul, South Korea.ORCID 0000-0002-9477-7421

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe goal of the study was to spatially validate intratumoral subregions (tumor habitat) using physiologic magnetic resonance imaging (MRI) on the pathology of the isocitrate dehydrogenase (IDH)-wild-type whole-glioblastoma sample.

methodsData from 20 patients (168 slides) were obtained from the Ivy Glioblastoma Atlas Project. On MRI, tumor habitats were defined using voxel-wise clustering of the apparent diffusion coefficient and cerebral blood volume maps for contrast-enhancing lesions (CEL) and non-enhancing lesions (NEL). On pathology slides, normalized areas of leading-edge, infiltrating tumor (IT), cellular tumor (CT), hypervascular lesion (CThypervascular), and perinecrotic lesion (CTperinecrotic) were obtained. Gross specimen was coregistered on MRI and correlation between pathology-MRI habitats was calculated. RNA sequencing of 67 samples was assessed using 4 Neftel subtypes and further correlated with pathology.

resultsSix tumor habitats were identified: hypervascular, hypovascular cellular, and hypovascular hypocellular habitats for CEL and NEL. CT was correlated with hypovascular cellular habitat in CEL (r = 0.238, P = .005). IT was correlated with hypovascular cellular habitat in NEL (r = 0.294, P = .017). CThypervascular was correlated with hypervascular habitat in NEL (r = 0.195, P = .023). CTperinecrotic was correlated with imaging necrosis (r = 0.199, P = .005). Astrocyte-like subtypes were correlated with IT (r = 0.256, P < .001), while mesenchymal-like subtypes were correlated with CTperinecrotic area (r = 0.246, P < .001).

conclusionsPathologically matched tumor subregions were CT with hypovascular cellular habitat in CEL and infiltrative tumor with hypovascular cellular habitat in NEL. Identification of the most aggressive, as well as infiltrative tumor portion, can be achieved using noninvasive MRI tumor habitats.

Indexed as

Brain NeoplasmsGlioblastomaIsocitrate DehydrogenaseMagnetic Resonance ImagingTumor MicroenvironmentAdultAgedFemaleHumansMaleMiddle AgedPrognosisIsocitrate DehydrogenaseglioblastomaMRIpathologytumor subregionsvalidation

Identifiers

PMID39177498
PMCPMC11726254

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.